The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ Brekiya (dihydroergotamine mesylate) injection ...

Brekiya consists of dihydroergotamine mesylate, an ergotamine derivative, in a single-dose autoinjector for subcutaneous administration.

Amneal Pharmaceuticals (NASDAQ:AMRX) continues to see significant institutional activity, signaling its relevance within the ...

The article summarizes recent health news, highlighting Mexico's suspension of poultry imports from Brazil due to bird flu, ...

The US Food and Drug Administration has granted approval to Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate ...

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q1 CY2025, but ...

Novo Nordisk's CEO, who led its boom driven by obesity and diabetes medications only to see that success stall, is stepping ...

Rite Aid has agreed to sell over 1,000 pharmacy assets to CVS, Walgreens, and others amid bankruptcy. Meanwhile, the health sector sees developments, including promising HIV vaccine trials, a rise in ...

The U.S. Food and Drug Administration has approved Amneal Pharmaceuticals' self-administered migraine drug, giving way to a ...

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and ...

The company said the injection is the first and only dihydroergotamine (DHE) autoinjector for treating migraine and cluster ...

An airline passenger who declared prescription medication that tested positive for methamphetamine was released on a $20,000 personal recognizance bond Wednesday. Mark Edwin Chaco Ocampo ...